STERIS plc

NYSE:STE Aktierapport

Börsvärde: US$21.2b

STERIS Framtida tillväxt

Future kriterier kontrolleras 1/6

STERIS förväntas öka intäkter och intäkter med 9.5% respektive 6.2% per år. EPS förväntas tillväxt med 9.6% per år. Avkastningen på eget kapital förväntas bli 12.8% om 3 år.

Viktig information

9.5%

Tillväxttakt i vinsten

9.57%

Tillväxttakt för EPS

Medical Equipment vinsttillväxt16.1%
Intäkternas tillväxttakt6.2%
Framtida avkastning på eget kapital12.80%
Bevakning av analytiker

Good

Senast uppdaterad13 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Uppdatering av berättelse • May 11

STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside

Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.
Uppdatering av berättelse • Apr 26

STE: Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).
Uppdatering av berättelse • Apr 11

STE: Completed Buyback And Stable Assumptions Will Support Future Upside

Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.
Uppdatering av berättelse • Mar 28

STE: Completed Buyback And Refined Assumptions Will Support Future Upside

Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.
Analysartikel • Mar 24

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...
Uppdatering av berättelse • Mar 11

STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.
Uppdatering av berättelse • Feb 25

STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside

Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.
Uppdatering av berättelse • Feb 10

STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View

Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.
Seeking Alpha • Feb 06

STERIS: A Bump In The Road For A Reliable Name

Summary STERIS offers a resilient, high-quality business model with some premium valuation, benefiting from hard-to-replicate sterilization networks and stable healthcare procedure volumes. Recent quarterly results included on-target 8% organic revenue growth but margin pressure from tariffs, with management raising tariff impact guidance by $10 million. STE stands to gain from stricter ethylene oxide (EtO) regulations, as compliance costs favor large, established players and will drive more outsourcing to its facilities. While not deeply undervalued, STE provides credible GARP appeal, stable cash flows, and less execution risk versus more volatile medtech peers. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jan 27

STE: Share Repurchases And Stable Outlook Will Support A Fair View

Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).
Uppdatering av berättelse • Jan 10

STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook

Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.
Analysartikel • Jan 09

Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysartikel • Dec 26

Earnings Tell The Story For STERIS plc (NYSE:STE)

With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...
Uppdatering av berättelse • Dec 23

STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook

Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).
Uppdatering av berättelse • Dec 09

STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook

Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).
Uppdatering av berättelse • Nov 25

STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance

Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.
Uppdatering av berättelse • Nov 07

STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value

Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.
Analysartikel • Oct 27

Is STERIS (NYSE:STE) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Uppdatering av berättelse • Sep 05

Healthcare Demand And Facility Expansion Will Create Value

With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.
Analysartikel • Aug 28

Calculating The Fair Value Of STERIS plc (NYSE:STE)

Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...
Analysartikel • Aug 07

STERIS (NYSE:STE) Is Paying Out A Larger Dividend Than Last Year

The board of STERIS plc ( NYSE:STE ) has announced that it will be increasing its dividend by 11% on the 26th of...
Analysartikel • Jul 06

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) saw a double-digit share price rise of over 10% in the past couple of months on the NYSE. The...
Seeking Alpha • Mar 22

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'

Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking Alpha
Seeking Alpha • Nov 18

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'

Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking Alpha
Seeking Alpha • Sep 16

Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued

Summary I reiterate a 'Hold' rating for Steris stock with a fair value of $220 per share, citing strong healthcare growth and overvaluation concerns. The divestiture of the dental business and acquisition of Surgical Instrumentation assets will allow Steris to focus on core healthcare and AST businesses. Steris reported 5.4% organic revenue growth and 7% adjusted EPS growth, driven by a 7.2% increase in AST business and strong healthcare performance. Despite strategic moves, cautious outlook on healthcare capital equipment spending due to high-interest rates supports maintaining a 'Hold' rating. Read the full article on Seeking Alpha
User avatar
Ny berättelse • Aug 20

Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector

Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.
Seeking Alpha • Aug 13

Steris: Q2 Numbers Solidify Buy Thesis

Summary STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base. I've revised our estimate on the intrinsic worth of the business to $270 per share, reiterating a buy. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NYSE:STE - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
3/31/20297,1861,045N/AN/A2
3/31/20286,7729849781,4277
3/31/20276,3618878441,2758
3/31/20265,9367829721,341N/A
12/31/20255,8287099171,267N/A
9/30/20255,7026899611,301N/A
6/30/20255,5716489091,264N/A
3/31/20255,4606107781,148N/A
12/31/20245,3986177511,142N/A
9/30/20245,3265916801,101N/A
6/30/20245,235561594996N/A
3/31/20245,139551613973N/A
12/31/20234,6831,036594934N/A
9/30/20234,6011,012535849N/A
6/30/20234,563576494806N/A
3/31/20234,536557395757N/A
12/31/20224,784-28349713N/A
9/30/20224,777-8399752N/A
6/30/20224,773377472819N/A
3/31/20224,223285397685N/A
12/31/20214,248279412701N/A
9/30/20213,848250400662N/A
6/30/20213,407286424653N/A
3/31/20213,108397450690N/A
12/31/20203,057433476701N/A
9/30/20203,022424400627N/A
6/30/20203,003413384615N/A
3/31/20203,031408376591N/A
12/31/20192,976393N/A570N/A
9/30/20192,898336N/A573N/A
6/30/20192,840319N/A548N/A
3/31/20192,782304N/A540N/A
12/31/20182,730269N/A490N/A
9/30/20182,696316N/A467N/A
6/30/20182,651303N/A478N/A
3/31/20182,620291N/A458N/A
12/31/20172,585243N/A463N/A
9/30/20172,570144N/A453N/A
6/30/20172,582120N/A424N/A
3/31/20172,613110N/A424N/A
12/31/20162,616142N/A439N/A
9/30/20162,588167N/A364N/A
6/30/20162,431135N/A294N/A
3/31/20162,233111N/A255N/A
12/31/20152,04294N/A185N/A
9/30/20151,897113N/A221N/A
6/30/20151,870135N/A241N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: STE s prognostiserade vinsttillväxt ( 9.5% per år) är över sparkvoten ( 3.5% ).

Resultat vs marknad: STE s intäkter ( 9.5% per år) förväntas växa långsammare än marknaden för US ( 16.9% per år).

Höga tillväxtresultat: STE s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: STE s intäkter ( 6.2% per år) förväntas växa långsammare än marknaden för US ( 11.9% per år).

Hög tillväxtintäkter: STE s intäkter ( 6.2% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: STE s avkastning på eget kapital förväntas bli låg om 3 år ( 12.8 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/27 11:25
Aktiekurs vid dagens slut2026/05/27 00:00
Intäkter2026/03/31
Årlig intjäning2026/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

STERIS plc bevakas av 18 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Michael PolarkBaird
Erin Wilson WrightBofA Global Research
David TurkalyCitizens JMP Securities, LLC